Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 1, 2013
Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. The completion of this...
-
Oct 30, 2013
Boston Scientific Corporation (NYSE:BSX) today announced the first German patient enrolment in the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization, a prospective multicentre...
-
Oct 30, 2013
Boston Scientific Corporation (NYSE:BSX) ha anunciado hoy la primera inscripción en el registro EWOLUTION con la utilización del dispositivo WATCHMAN en la vida real. Se trata de un registro...
-
Oct 28, 2013REDUCE-HTN Data Presented Today at TCT Demonstrate Excellent Safety Profile
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented...
-
Oct 28, 2013Il dispositivo per la sostituzione transcatetere della valvola aortica (TAVR, Transcatheter Aortic Valve Replacement) permette il posizionamento preciso, garantendo ai medici una possibilità di controllo senza precedenti
Boston Scientific Corporation (NYSE: BSX) ha ricevuto il marchio CE per la valvola Lotus™, la tecnologia innovativa d e ll'azienda per la sostituzione transcatetere della valvola aortica (TAVR)....
-
Oct 28, 2013
Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control Boston Scientific Corporation (NYSE: BSX) has received CE...
-
Oct 28, 2013REDUCE-HTN Data Presented Today at TCT Demonstrate Excellent Safety Profile
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented...
-
Oct 8, 2013University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity
An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are significant differences in battery longevity...
-
Sep 26, 2013REPRISE-II-Daten wurden im Rahmen des PCR London Valves Course zum "Best Abstract 2013" gekürt
Boston Scientific Corporation (NYSE: BSX) hat die positiven 6-Monats-Daten für die ersten 60 Probanden der klinischen Studie REPRISE II vorgelegt, die die Sicherheit und Effizienz...
-
Sep 25, 2013Boston Scientific comunica i risultati positivi a sei mesi dello studio clinico sulla valvola Lotus™I dati di REPRISE II premiati con il Miglior Abstract 2013 al PCR London Valves Course
La Boston Scientific Corporation (NYSE: BSX) ha comunicato i risultati positivi a sei mesi dei primi 60 pazienti arruolati nello studio clinico REPRISE II che valutava la sicurezza e la...